Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydrochloride, Pargyline
2. Pargyline Hydrochloride
1. 555-57-7
2. N-methyl-n-propargylbenzylamine
3. Pargylamine
4. Paragyline
5. Eudatin
6. Supirdyl
7. N-benzyl-n-methylprop-2-yn-1-amine
8. Pargylin
9. Eutonyl
10. N-methyl-n-2-propynylbenzylamine
11. Benzenemethanamine, N-methyl-n-2-propynyl-
12. Benzyl-methyl-2-propinylamin
13. Benzylmethylpropargylamine
14. N-benzyl-n-methyl-2-propynylamine
15. N-methyl-n-benzylpropynylamine
16. Eutron
17. Methylbenzylpropynylamine
18. Mo 911
19. N-benzyl-n-methyl-2-propyn-1-amine
20. Pargyline Chloride
21. Benzylamine, N-methyl-n-2-propynyl-
22. Pargyline (inn)
23. Pargyline [inn]
24. A 19120
25. Chembl673
26. 9mv14s8g3e
27. Chebi:7930
28. N-methyl-n-(phenylmethyl)prop-2-yn-1-amine
29. Benzyl-methyl-prop-2-ynyl-amine
30. Benzyl(methyl)(prop-2-yn-1-yl)amine
31. Pargilina
32. Pargylinum
33. Pargyline [inn:ban]
34. Pargylinum [inn-latin]
35. Pargilina [inn-spanish]
36. Benzyl-methyl-2-propinylamin [czech]
37. Nsc43798
38. Ccris 6740
39. Benzylmethylpropynylamine
40. Ncgc00015841-02
41. Cas-306-07-0
42. Einecs 209-101-6
43. Lopac-p-8013
44. Brn 1938132
45. Unii-9mv14s8g3e
46. Ai3-62058
47. Eutonyl (salt/mix)
48. Spectrum_000641
49. Pargyline [mi]
50. Prestwick0_000183
51. Prestwick1_000183
52. Prestwick2_000183
53. Prestwick3_000183
54. Spectrum2_001039
55. Spectrum3_000540
56. Spectrum4_000469
57. Spectrum5_001030
58. Pargyline [vandf]
59. Cbchromo1_000308
60. Pargyline [who-dd]
61. Schembl2045
62. Lopac0_001022
63. Bspbio_000105
64. Bspbio_002159
65. Kbiogr_000918
66. Kbioss_001121
67. 2-12-00-00548 (beilstein Handbook Reference)
68. Divk1c_000053
69. Spbio_001257
70. Spbio_002026
71. Bpbio1_000117
72. Gtpl7262
73. Dtxsid3023423
74. Dpwpwrlqfgfjfi-uhfffaoysa-
75. Hy-a0091a
76. Kbio1_000053
77. Kbio2_001121
78. Kbio2_003689
79. Kbio2_006257
80. Kbio3_001659
81. Ninds_000053
82. Hms3604i04
83. N-benzyl-n-methyl-2-propinylamine
84. Pargyline Hydrochloride (salt/mix)
85. Bdbm50172756
86. Mfcd00008576
87. Zinc53084618
88. 2-propynylamine, N-benzyl-n-methyl-
89. N-methyl-n-(2-propynyl)benzylamine-
90. Akos009027469
91. N-benzyl-n-methyl-prop-2-yn-1-amine
92. N-methyl-n-propargylbenzylamine, 97%
93. Ccg-205102
94. Cs-4685
95. Db01626
96. Sdccgsbi-0050995.p005
97. Idi1_000053
98. N-benzyl-n-methyl-2-propyn-1-amine #
99. N-methyl-n-(2-propyn-1-yl)benzylamine
100. Ncgc00015841-01
101. Ncgc00015841-03
102. Ncgc00015841-04
103. Ncgc00015841-05
104. Ncgc00015841-06
105. Ncgc00015841-07
106. Ncgc00015841-18
107. Ncgc00024240-03
108. As-75650
109. Sbi-0050995.p004
110. Db-072009
111. Ab00053516
112. Ft-0700064
113. M2618
114. C07414
115. D08453
116. T72610
117. Ab00053516_13
118. N-benzyl-n-methylprop-2-yn-1-amine,hydrochloride
119. Q781329
120. W-105554
121. Brd-k83597974-003-05-7
| Molecular Weight | 159.23 g/mol |
|---|---|
| Molecular Formula | C11H13N |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 3 |
| Exact Mass | 159.104799419 g/mol |
| Monoisotopic Mass | 159.104799419 g/mol |
| Topological Polar Surface Area | 3.2 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 159 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of moderate to severe hypertension.
Pargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Monoamine Oxidase Inhibitors
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)
C - Cardiovascular system
C02 - Antihypertensives
C02K - Other antihypertensives
C02KC - Mao inhibitors
C02KC01 - Pargyline
MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Pargylamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pargylamine, including repackagers and relabelers. The FDA regulates Pargylamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pargylamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pargylamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pargylamine supplier is an individual or a company that provides Pargylamine active pharmaceutical ingredient (API) or Pargylamine finished formulations upon request. The Pargylamine suppliers may include Pargylamine API manufacturers, exporters, distributors and traders.
click here to find a list of Pargylamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Pargylamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pargylamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pargylamine GMP manufacturer or Pargylamine GMP API supplier for your needs.
A Pargylamine CoA (Certificate of Analysis) is a formal document that attests to Pargylamine's compliance with Pargylamine specifications and serves as a tool for batch-level quality control.
Pargylamine CoA mostly includes findings from lab analyses of a specific batch. For each Pargylamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pargylamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Pargylamine EP), Pargylamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pargylamine USP).
LOOKING FOR A SUPPLIER?
